In a groundbreaking new study published in Nature, researchers from the Weizmann Institute of Science, in collaboration with Sheba Medical Center and the Mayo Clinic, unveiled the first high-resolution genetic atlas of the healthy human liver at 2-micron precision. This unprecedented map reveals a far more intricate and nuanced division of labor in the human liver than what was previously understood. Their discoveries highlight why specific liver regions show differential vulnerability to diseases such as metabolic dysfunction and fatty liver disease, thus opening new avenues for targeted therapies.

The technological leap enabling this discovery comes from advances in single-cell RNA sequencing combined with spatial transcriptomics—techniques that allow scientists to identify gene activity in individual cells while precisely mapping their spatial context within the tissue. However, generating such a comprehensive map demanded access to exquisitely healthy tissue, a challenge overcome by studying liver samples from living donors who altruistically provided a part of their liver for transplantation. The liver’s unique regenerative ability enables these donors to remain healthy despite partial tissue removal. With contributions from surgical teams at Sheba Medical Center and the Mayo Clinic, eight samples from healthy donors were meticulously analyzed to create this detailed gene expression atlas.

Intriguingly, the new atlas disrupts the longstanding model that divided liver lobules into three functional zones based merely on nutrient and oxygen gradients. Instead, the researchers discovered eight distinct regions, each characterized by unique genetic signatures and metabolic roles. This fine-grained map enables scientists worldwide to investigate why diseases preferentially affect different lobule regions—for example, how metabolic diseases often originate near the lobule centers while viral and autoimmune inflammations tend to occur around the periphery. Moreover, the spatial atlas provides insights into the regional predisposition of liver cancers and metastatic tumors, linking cellular function to disease localization.

To elucidate evolutionary variations, the team compared the human liver atlas with analogous maps from mice, pigs, and cows. Interestingly, while blood flows from the lobule’s periphery to its center in all these mammals, resulting in oxygen and nutrient gradients, cellular activity patterns differ notably. In most mammals, cells near the lobule center exhibit lower metabolic activity due to resource scarcity. Humans, however, display a unique adaptation: central lobule cells maintain robust metabolic activity, engaging in functions such as fatty acid synthesis from excess energy, glucose production during fasting, toxin filtration, and bile secretion. This divergence may explain the human liver’s exceptional metabolic flexibility alongside its susceptibility to modern lifestyle diseases.

Another remarkable species-specific distinction centers on glucose handling within the liver. Often described as the body’s “fuel tank,” the liver optimally stores glucose during feeding and releases it during fasting. The study reveals that in humans, glucose uptake primarily occurs at the lobule centers, in stark contrast to mice where this activity is peripheral. This central localization allows for a highly efficient carbohydrate storage and release system, with peripheral cells converting lactate to glucose, thus complementing energy supply during fasting. While effective under natural dietary conditions, this system’s efficiency may paradoxically contribute to fat accumulation and liver fibrosis in response to today’s calorie-rich, fat-heavy diets.

To counterbalance the intense metabolic demands and resulting cellular stress, the human liver appears to have evolved a specialized mechanism for cellular turnover within the lobule centers. The study spotlighted Kupffer cells—specialized resident immune cells known for scavenging and recycling cellular debris. Unlike other mammals where Kupffer cells patrol the lobule periphery near blood entry points, in humans these cells concentrate at the lobule core. This strategic relocation likely helps manage the elevated cellular wear in this region, preventing tissue damage and maintaining liver homeostasis amid high metabolic throughput.

The practical implications of this atlas extend beyond basic biology into translational medicine. By comparing healthy liver cells with their counterparts in fatty liver disease—a condition tightly linked to obesity and diabetes—the researchers observed that cells accumulating fat initiate a defensive genetic program. They simultaneously downregulate genes involved in fat synthesis and uptake while upregulating genes promoting fat breakdown. Nonetheless, fat accumulation impairs mitochondrial function, reducing the organelles’ capacity to metabolize fats efficiently. Such molecular insights pave the way for targeted interventions that might reinforce these natural protective mechanisms or rectify their decline during disease progression.

Further integrating genetics with spatial information, the atlas allows precise pinpointing of zones most vulnerable to specific pathologies. This could revolutionize therapeutic development by enabling gene-targeted drugs or gene editing tools to focus on discrete lobule regions, minimizing off-target effects and maximizing efficacy. Moreover, the approach exemplified in this study—constructing single-cell-resolution genetic atlases from exceptional healthy donor tissue—sets a new standard for investigating human organs. Applied broadly, it promises to deepen our understanding of complex organ architectures and functions in health and disease.

In essence, the liver atlas represents a quantum leap in liver biology, shifting our perception from fuzzy, generalized zones to a vibrant, heterogeneous landscape of cellular specialization. This meticulous spatial and genetic dissection has profound implications for how we understand metabolism, immune defense, disease susceptibility, and regeneration in humans. By uncovering the liver’s secret organizational patterns, it also offers a fresh perspective on why human livers uniquely adapt to and sometimes falter under modern dietary pressures and metabolic challenges.

The study was spearheaded by Dr. Oran Yakubovsky alongside Prof. Shalev Itzkovitz and a multidisciplinary team spanning molecular biology, surgery, and computational analysis. Through their collaborative efforts, they leveraged innovative sampling approaches and sophisticated genomic technologies to deliver this illuminating atlas, ushering in a new era of precision hepatology.

Looking forward, the researchers envisage that their atlas will serve as a foundational resource for scientists probing liver diseases, drug metabolism, and regenerative medicine. The robust datasets and spatial frameworks provided could also facilitate artificial intelligence and machine learning applications aimed at modeling liver function and predicting disease course. Such integrative research holds the promise of transforming patient care, optimizing liver transplantation, and tailoring personalized therapies in hepatology.

This exciting accomplishment underscores how harnessing cutting-edge technology, clinical innovation, and human generosity can intersect to unravel the complex biology of vital organs. As techniques evolve, similar high-resolution atlases of other human organs may soon illuminate uncharted territories of cellular specialization, architectural nuances, and disease mechanisms, ultimately advancing medicine and human health.

Subject of Research: Spatial genetic mapping and functional zonation of the healthy human liver

Article Title: A spatial atlas of the healthy human liver from live donors

News Publication Date: 15-Apr-2026

Web References: https://www.nature.com/articles/s41586-026-10377-y

References: DOI 10.1038/s41586-026-10377-y

Keywords: liver atlas, spatial transcriptomics, single-cell RNA sequencing, lobule zonation, hepatocyte function, Kupffer cells, fatty liver disease, metabolic zonation, liver regeneration, glucose metabolism, mitochondrial dysfunction, human liver disease

The team of researchers at the Medical Research Council (MRC) Mitochondrial Biology Unit, University of Cambridge, employed cutting-edge cryo-electron microscopy to visualize the mitochondrial pyruvate carrier with astonishing resolution, approximately 165,000 times magnified. This approach illuminated the carrier’s molecular architecture and mechanistic operation, akin to a canal lock system, detailing how pyruvate traverses the impermeable inner mitochondrial membrane to fuel ATP synthesis—the universal energy currency of life.

Conceived in theory in 1971, the mitochondrial pyruvate carrier eluded direct observation for decades due to technical challenges posed by its minuscule size and complex membrane environment. With advancements in imaging technologies, Dr. Sotiria Tavoulari and colleagues have now resolved its composition and confirmed how the transporter shuttles pyruvate with remarkable precision. Pyruvate’s import into mitochondria amplifies cellular energy output by up to fifteenfold, underpinning the metabolic vigor of most eukaryotic organisms.

The inner mitochondrial membrane serves as a formidable barrier impermeable to most metabolites, including pyruvate. To navigate this, the carrier utilizes a sophisticated gating mechanism. As elucidated through their structural studies, an outer gate opens to admit pyruvate molecules, then closes before an inner gate opens, permitting their smooth passage into the mitochondrial matrix. This molecular choreography closely mirrors the operation of canal locks that control boat passage, but on a nanoscopic scale.

Professor Edmund Kunji of the MRC Mitochondrial Biology Unit expounded on the elegant gating mechanism: "Much like a canal lock with sequential gates regulating watercraft movement, the pyruvate carrier employs two molecular gates to ensure the directional and controlled translocation of its substrate. This prevents leakage and maintains metabolic fidelity within the cell."

Understanding the carrier’s structure is more than a scientific triumph—it has profound clinical implications. Given its central role in energy metabolism, the mitochondrial pyruvate carrier emerges as a promising therapeutic target across a spectrum of diseases. Conditions such as diabetes, fatty liver disease, Parkinson’s disease, and certain cancers are fundamentally linked to metabolic dysregulation, where modulating pyruvate transport could alter disease trajectories.

In diseases like fatty liver, excessive fat accumulation in hepatic cells poses life-threatening risks. By blocking the pyruvate carrier, cells may be coerced into metabolizing stored fats, potentially mitigating disease progression. This metabolic rerouting highlights the carrier’s role as a metabolic gatekeeper, steering substrate utilization in response to physiological needs or pharmacological intervention.

The cancer metabolism paradigm also intersects with mitochondrial pyruvate transport. Tumor cells, notably within some aggressive prostate cancers, overexpress pyruvate carriers to meet heightened energy demands. Interrupting this supply line impairs cancer cell vitality, effectively starving them by cutting off their metabolic fuel. Such insights pave the way for innovative anticancer strategies centered on metabolic inhibition.

Beyond metabolic diseases, the mitochondrial pyruvate carrier intriguingly influences hair follicle biology. Hair follicle cells depend on the generation of lactate for activation and growth. When pyruvate entry into mitochondria is impeded, it is diverted toward lactate production, potentially reactivating follicles and reversing hair loss. This novel metabolic link suggests unforeseen applications of carrier inhibitors in dermatology.

Central to these therapeutic possibilities is the ability to design drugs with precise molecular targeting. The cryo-electron microscopy data not only reveal the carrier’s structure but also demonstrate how specific inhibitors lodge within the transporter, effectively jamming its function. Visualizing this “spanner in the works” empowers drug developers to craft molecules that can selectively modulate the carrier’s action with minimal side effects.

The implications of this discovery echo loudly across biomedical research. Mitochondria, once viewed merely as cellular power units, increasingly are understood as complex regulatory hubs controlling health and disease. The mitochondrial pyruvate carrier exemplifies this complexity, standing at the intersection of metabolism, signaling, and pathology. Unlocking its secrets heralds a new era of mitochondrial medicine.

This breakthrough owes much to the collaborative efforts of scientists across continents, including key contributions from Vanessa Leone’s group at the Medical College of Wisconsin, Lucy Forrest’s team at the National Institutes of Health, and Jan Steyaert’s laboratory at the Free University of Brussels. Such transatlantic partnerships underscore the global nature of cutting-edge biomedical inquiry.

The study, published in Science Advances on April 18, 2025, marks a milestone in mitochondrial biology and metabolic research. It not only clarifies fundamental cellular processes but shines a guiding light toward the development of targeted therapies for complex diseases that touch millions worldwide, potentially transforming clinical practice in the not-so-distant future.

In sum, the demystification of the mitochondrial pyruvate carrier’s molecular basis is a landmark achievement that integrates structural biology, cellular physiology, and therapeutic innovation. As we continue to explore the microscopic machinations powering life, these findings provide a potent reminder of the vast potential residing within our cells, waiting to be harnessed for human health.

Subject of Research: People

Article Title: Molecular basis of pyruvate transport and inhibition of the human mitochondrial pyruvate carrier

News Publication Date: 18-Apr-2025

Web References: http://dx.doi.org/10.1126/sciadv.adw1489

References: Sichrovsky, M, Lacabanne, D, Ruprecht, JJ & Rana, JJ et al. Molecular basis of pyruvate transport and inhibition of the human mitochondrial pyruvate carrier. Sci Adv; 18 Apr 2025; DOI: 10.1126/sciadv.adw1489

Keywords: Sugars, Fatty liver disease, Metabolism, Cellular energy, Atomic structure, Molecular structure